The European GLP-1 agonists market is booming, projected to reach €3.94 billion by 2025 with a 5.90% CAGR through 2033. Driven by rising diabetes prevalence and innovative drugs like Semaglutide and Liraglutide, this market analysis reveals key trends, challenges, and leading companies like Novo Nordisk and Eli Lilly. Discover insights into segment growth and future projections.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.